Vir Biotechnology to Participate in the Jefferies 2025 London Healthcare Conference

SAN FRANCISCO--(BUSINESS WIRE)-- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will present at the Jefferies 2025 London Healthcare Conference on Tuesday, November 18 at 2:00 p.m. GMT / 9:00 a.m. ET / 6:00 a.m. PT in London, United Kingdom.

A live webcast of the presentation will be made available under Events & Presentations in the Investors section of the Vir Biotechnology website and will be archived for 30 days.

About Vir Biotechnology

Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes programs for chronic hepatitis delta and multiple dual-masked T-cell engagers across validated targets in solid tumor indications. Vir Biotechnology also has a portfolio of preclinical programs across a range of infectious diseases and oncologic malignancies. Vir Biotechnology routinely posts information that may be important to investors on its website.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251107857542/en/

Media Contact
[email protected]

Investors Contact
[email protected]

Source: Vir Biotechnology, Inc.

You May Also Be Interested In

• KKR Acquires Leading Japanese Beauty Platform Ci FLAVORS
• GreenTree Hospitality Group Ltd. Reports Second Quarter of 2026 Financial Results
• Tigo Energy and Ingeteam Sign Certificate of Compatibility